Märkl et al., 2023 - Google Patents
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanomaMärkl et al., 2023
View HTML- Document ID
- 6421206495389877139
- Author
- Märkl F
- Benmebarek M
- Keyl J
- Cadilha B
- Geiger M
- Karches C
- Obeck H
- Schwerdtfeger M
- Michaelides S
- Briukhovetska D
- Stock S
- Jobst J
- Müller P
- Majed L
- Seifert M
- Klüver A
- Lorenzini T
- Grünmeier R
- Thomas M
- Gottschlich A
- Klaus R
- Marr C
- von Bergwelt-Baildon M
- Rothenfusser S
- Levesque M
- Heppt M
- Endres S
- Klein C
- Kobold S
- Publication year
- Publication venue
- Journal for Immunotherapy of Cancer
External Links
Snippet
Background Melanoma is an immune sensitive disease, as demonstrated by the activity of immune check point blockade (ICB), but many patients will either not respond or relapse. More recently, tumor infiltrating lymphocyte (TIL) therapy has shown promising efficacy in …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Burger et al. | CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy | |
| Hou et al. | Navigating CAR-T cells through the solid-tumour microenvironment | |
| Feins et al. | An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer | |
| Majzner et al. | Tumor antigen escape from CAR T-cell therapy | |
| Friedman et al. | Effective targeting of multiple B-cell maturation antigen–expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells | |
| Lee et al. | An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma | |
| Liu et al. | FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18. 2-targeted CAR-T against pancreatic cancer | |
| Johnson et al. | Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma | |
| Albert et al. | From mono-to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo | |
| Künkele et al. | Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility | |
| Kim et al. | Redirection of genetically engineered CAR-T cells using bifunctional small molecules | |
| Suarez et al. | Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model | |
| JP7033549B2 (en) | Cell-based neoantigen vaccine and its use | |
| Tai et al. | Targeting B-cell maturation antigen in multiple myeloma | |
| Yu et al. | Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients | |
| Künkele et al. | Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas–FasL-dependent AICD | |
| Chu et al. | CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma | |
| Topalian et al. | Cancer immunotherapy comes of age | |
| Singh et al. | Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma | |
| Del Vecchio et al. | Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas | |
| Sommaggio et al. | Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells | |
| BR112020025048A2 (en) | BCMA CHEMICAL ANTIGEN RECEPTORS AND USES OF THE SAME | |
| Hoseini et al. | Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2 | |
| Dai et al. | Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer | |
| Annesley et al. | The evolution and future of CAR T cells for B‐cell acute lymphoblastic leukemia |